Topic: Health
Researchers at Baylor College of Medicine have developed a new experimental drug called CS18 that can help cancer treatments work against tumors that are resistant to therapy. The study, published in Science Advances, shows that CS18 can target a key control center involved in several cancer-promoting processes and reduce the defenses that help cancer cells survive therapy.
Researchers at Baylor College of Medicine have developed an experimental drug called CS18 that may help cancer treatments work against tumors that have become resistant to therapy. The study, published in Science Advances, provides early evidence supporting further investigation of CS18 as a possible future cancer treatment.
Therapeutic resistance is a major obstacle to achieving effective and durable cancer treatments. While some therapies are effective at the beginning, many patients eventually relapse because cancer cells can activate compensatory and convergent biological pathways that allow them to overcome the toxic effects of therapy, promoting survival.
The researchers targeted TopBP1, which they describe as a 'biological switchboard' because it helps regulate multiple pathways associated with cancer growth and survival. They wanted to determine whether disrupting this central control point could produce longer-lasting treatment responses and help overcome resistance.
To find a compound capable of blocking BRCT7/8, the researchers screened thousands of chemicals using computer modeling and laboratory experiments. This search identified a compound known as 3B6. The team then modified 3B6 and tested numerous versions of the molecule, eventually identifying CS18 as the most effective candidate.
CS18 was tested across several types of cancer cells, including triple-negative breast cancer, ovarian cancer, lung adenocarcinoma, lung squamous cell carcinoma, and acute myeloid leukemia. The results showed that CS18 reduced the defenses that help cancer cells survive therapy and increased the activity of genes that stop uncontrolled cancer growth.
The researchers also found that combining CS18 with existing cancer drugs made them more effective against cancer cells. In fact, adding CS18 to osimertinib restored the sensitivity of lung cancer cells that were already resistant to it.
Why It Matters
This breakthrough has the potential to save thousands of lives by making cancer treatments more effective and increasing their chances of success. As India struggles with a growing cancer burden, finding new ways to combat this disease is crucial for public health.
Key Facts
- Researchers at Baylor College of Medicine have developed an experimental drug called CS18 that can help cancer treatments work against tumors resistant to therapy.
- CS18 targets TopBP1, a 'biological switchboard' that helps regulate multiple pathways associated with cancer growth and survival.
- The researchers tested CS18 across several types of cancer cells and found it reduced the defenses that help cancer cells survive therapy.
- Combining CS18 with existing cancer drugs made them more effective against cancer cells.
- CS18 was developed through a process of screening thousands of chemicals using computer modeling and laboratory experiments.
Key Terms
- TopBP1
- A 'biological switchboard' that helps regulate multiple pathways associated with cancer growth and survival.
- BRCT7/8
- The part of TopBP1 that CS18 targets to block its cancer-promoting activities.
Implications
This breakthrough has the potential to save thousands of lives by making cancer treatments more effective and increasing their chances of success. As India struggles with a growing cancer burden, finding new ways to combat this disease is crucial for public health.
Leave a comment